Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer

被引:58
|
作者
Bjork, T
Piironen, T
Pettersson, K
Lovgren, T
Stenman, UH
Oesterling, JE
Abrahamsson, PA
Lilja, H
机构
[1] LUND UNIV,UNIV HOSP,DEPT UROL,MALMO,SWEDEN
[2] LUND UNIV,UNIV HOSP,DEPT CLIN CHEM,MALMO,SWEDEN
[3] UNIV TURKU,BIOCITY,DEPT BIOTECHNOL,TURKU,FINLAND
[4] HELSINKI UNIV HOSP,DEPT CLIN CHEM,HELSINKI,FINLAND
[5] UNIV MICHIGAN,MICHIGAN PROSTATE INST,ANN ARBOR,MI
关键词
D O I
10.1016/S0090-4295(96)00486-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To compare different forms and ratios of serum prostate-specific antigen (PSA) to determine which form or ratio provides optimal diagnostic specificity and sensitivity in distinguishing between benign prostatic hyperplasia (BPH) and clinically localized prostate cancer. Methods. Serum samples were obtained from 47 patients with BPH and 39 with clinically localized prostate cancer. Patients with BPH underwent either transurethral resection of the prostate or transurethral microwave thermotherapy. Patients with prostate cancer, all of whom had no metastases on radionucleotide bone scans and no pelvic lymph node involvement, underwent either radical external beam radiation therapy or radical retropubic prostatectomy. All patients had pretreatment serum PSA levels between 1 and 20 ng/mL, The different forms of serum PSA (free PSA [PSA-F], PSA complexed to alpha(1)-antichymotrypsin [PSA-ACT], and total PSA [PSA-T]) were measured using different monoclonal antibodies against PSA and ACT and immunofluorometric assay techniques. Furthermore, three ratios (PSA-F/PSA-T, PSA-ACT/PSA-T, and PSAF/PSA-ACT) were calculated. Results. By receiver operating characteristic curve analysis, the performance of the different forms and ratios were compared. The PSA-F/PSA-T ratio had the greatest area under the curve (AUC, 0.776), significantly larger than that for PSA-T (0.612; P = 0.024). For PSA-ACT/PSA-T, the AUC was 0.695 (P = 0.283 versus PSA-T) and 0.775 for PSA-F/PSA-ACT (P = 0.051 versus PSA-T). At a cutoff level <0, 17, PSA-F/PSA-T had a sensitivity of 79%, a specificity of 66%, and a positive predictive value of 66% compared with 74%, 38%, and 50%, respectively, for PSA-T at a cutoff level >4.0 ng/mL. Conclusions. The PSA-F/PSA-T ratio gives the best diagnostic performance compared with that for other forms and ratios of PSA and will reduce the number of prostatic biopsies in patients with BPH. Copyright 1996 by Elsevier Science Inc.
引用
收藏
页码:882 / 888
页数:7
相关论文
共 50 条
  • [1] Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer
    Mikolajczyk, SD
    Catalona, WJ
    Evans, CL
    Linton, HJ
    Millar, LS
    Marker, KM
    Katir, D
    Amirkhan, A
    Rittenhouse, HG
    [J]. CLINICAL CHEMISTRY, 2004, 50 (06) : 1017 - 1025
  • [2] COMPARISON OF DIFFERENT SERUM PROSTATE-SPECIFIC ANTIGEN MEASURES FOR EARLY PROSTATE-CANCER DETECTION
    CATALONA, WJ
    SMITH, DS
    [J]. CANCER, 1994, 74 (05) : 1516 - 1518
  • [3] Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer
    Zagars, GK
    Pollack, A
    [J]. RADIOTHERAPY AND ONCOLOGY, 1997, 44 (03) : 213 - 221
  • [4] Urinary/serum prostate-specific antigen ratio:: Comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection
    Irani, J
    Salomon, L
    Soulié, M
    Zlotta, A
    de la Taille, A
    Doré, B
    Millet, C
    [J]. UROLOGY, 2005, 65 (03) : 533 - 537
  • [5] Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels
    Furuya, Y
    Ohta, S
    Sato, N
    Kotake, T
    Sugano, I
    Nagao, K
    Masai, M
    [J]. ANTICANCER RESEARCH, 2001, 21 (2B) : 1317 - 1320
  • [6] Detection of prostate-specific antigen forms and other kallikreins in prostate cancer
    Jolivet-Reynaud, Colette
    Michel, Sandrine
    Ott, Catherine
    [J]. MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2008, 32 (01): : 24 - 30
  • [7] THE SOURCE OF PRETREATMENT SERUM PROSTATE-SPECIFIC ANTIGEN IN CLINICALLY LOCALIZED PROSTATE-CANCER - T, N, OR M
    ZAGARS, GK
    KAVADI, VS
    POLLACK, A
    VONESCHENBACH, AC
    SANDS, ME
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (01): : 21 - 32
  • [8] PROSTATE-SPECIFIC ANTIGEN AND RADIATION-THERAPY FOR CLINICALLY LOCALIZED PROSTATE-CANCER
    ZAGARS, GK
    POLLACK, A
    KAVADI, VS
    VONESCHENBACH, AC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (02): : 293 - 306
  • [9] The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer
    Partin, AW
    Carter, HB
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 1996, 23 (04) : 531 - +
  • [10] Detection of prostate cancer by prostate-specific antigen
    Egawa, S
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (03) : 130 - 134